MED11

Across TCGA pan-cancer cohorts, MED11 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MED11 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MED11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MED11 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and HNSC are the cancer types where MED11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.747	0.472	.008	16	view →
CCRCC	DFS	Tertile	IV	0.948	0.138	.024	9	view →
HNSC	DFS	Quartile	All	1.000	0.918	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MED11–LSCC (DFS)

Open the LSCC breakdown →